Jeremy Rubinstein

20PUBLICATIONS
94CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyAutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Oct 20, 2026
A real-world multi-institution experience of standard versus alternative dosing regimens of inotuzumab ozogamicin for relapsed/refractory paediatric B-cell acute lymphoblastic leukaemia.

|Sep 22, 2026
Boosting the Predictive Power of Virus-Specific T-Cell Clinical Trials via Generative Models.

|May 15, 2026
Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates.

|Sep 24, 2025
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.

Jeremy D Rubinstein, Giang Pham, Anusha Sridharan

|Apr 07, 2025
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

Sara K Silbert, Alexander W Rankin, Chloe N Hoang

|Mar 22, 2025
Posttransplant EBV-Positive Smooth Muscle Tumors in Children, Adolescents, and Young Adults: A Multi-Institution Experience.

Meghan Haney, Kaitlin J Devine, Ana C Xavier

Pageof 4

Frequent Collaborators

3 joint publications

Christopher E Dandoy

3 joint publications

Lauren Pommert

3 joint publications

Michael S Grimley

2 joint publications

Joseph Pressey